GlassScriptPhysician profile
Deepesh Kumar Yadav
NPI 1689202343
$864.86
in general payments reported to CMS, 2019-2025
17 companies · $720 in 2025
The $720 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $37.54 · 2022: $86.02 · 2023: $21.22 · 2025: $720.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $741.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $741.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $240.67 | 2023-2025 | Otezla, Krystexxa, Uplizna |
| Alnylam Pharmaceuticals INC. | $86.02 | 2022 | |
| Genzyme Corporation | $70.23 | 2021-2025 | |
| Glaxosmithkline, LLC. | $58.13 | 2025 | Benlysta |
| Abbvie INC. | $53.76 | 2025 | |
| Novartis Pharmaceuticals Corporation | $46.21 | 2025 | |
| Aurinia Pharma U.S., INC. | $45.16 | 2025 | Lupkynis |
| Neurocrine Biosciences, INC. | $34.28 | 2025 | |
| Actelion Pharmaceuticals US, INC. | $31.81 | 2025 | Opsynvi, Uptravi |
| Lilly USA, LLC | $29.85 | 2025 | Taltz |
| Genentech USA, INC. | $28.10 | 2025 | Gazyva |
| Octapharma USA, INC. | $27.72 | 2025 | Octagam Immune Globulin (Human) |
| Janssen Biotech, INC. | $27.63 | 2025 | Tremfya |
| Merck Sharp & Dohme LLC | $26.96 | 2025 | Capvaxive |
| Astrazeneca Pharmaceuticals LP | $22.51 | 2025 | Saphnelo |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $22.25 | 2025 | |
| Pfizer INC. | $13.57 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deepesh Yadav listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.